Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Lymphoma, T-Cell 2Pancreatic Neoplasms 1Oligodendroglioma 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 53Bevacizumab 33Radiotherapy 27Radiation 12Erlotinib Hydrochloride 12Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Irinotecan 6Vorinostat 5Sorafenib 5Sirolimus 5temsirolimus 4Magnetic Resonance Spectroscopy 4Immunoglobulin G 4Disulfides 4Carmustine 4veliparib 3plerixafor 3carmustine, poliferprosan 20 drug combination 3Radiosurgery 3Everolimus 3Dasatinib 3Bortezomib 3vandetanib 2tandutinib 2sargramostim 2poly ICLC 2pembrolizumab 2pazopanib 2ferric pyrophosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gliosarcoma × Depsipeptides × Clear all
NCT00085540 2017-01-02

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

National Cancer Institute (NCI)

Phase 1/2 Completed
50 enrolled 6 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡